Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Zhuqing Long, Jie Li, Jianghua Fan, Bo Li, Yukeng Du, Shuang Qiu, Jichang Miao, Jian Chen, Juanwu Yin, Bin Jing
INTRODUCTION: Multi-modal neuroimaging metrics in combination with advanced machine learning techniques have attracted more and more attention for an effective multi-class identification of Alzheimer's disease (AD), mild cognitive impairment (MCI) and health controls (HC) recently. METHODS: In this paper, a total of 180 subjects consisting of 44 AD, 66 MCI and 58 HC subjects were enrolled, and the multi-modalities of the resting-state functional magnetic resonance imaging (rs-fMRI) and the structural MRI (sMRI) for all participants were obtained...
2023: Frontiers in Aging Neuroscience
#22
JOURNAL ARTICLE
James F Burke, Kevin A Kerber, Kenneth M Langa, Roger L Albin, Vikas Kotagal
Lecanemab, a novel amyloid-sequestering agent, recently received accelerated Food and Drug Administration approval for the treatment of mild dementia due to Alzheimer disease (AD) and mild cognitive impairment (MCI). Approval was based on a large phase 3 trial, Clarity, which demonstrated reductions in amyloid plaque burden and cognitive decline with lecanemab. Three major concerns should give us pause before adopting this medication: Its beneficial effects are small, its harms are substantial, and its potential costs are unprecedented...
October 10, 2023: Neurology
#23
JOURNAL ARTICLE
Ekaterina Zotcheva, Bjørn Heine Strand, Catherine E Bowen, Bernt Bratsberg, Astanand Jugessur, Bo Lars Engdahl, Geir Selbaek, Hans-Peter Kohler, Jennifer R Harris, Jordan Weiss, Maja Weemes Grøtting, Sarah E Tom, Steinar Krokstad, Yaakov Stern, Asta Kristine Håberg, Vegard Skirbekk
BACKGROUND: Research shows that retirement age is associated with later-life cognition but has not sufficiently distinguished between retirement pathways. We examined how retirement age was associated with later-life dementia and mild cognitive impairment (MCI) for people who retired via the disability pathway (received a disability pension prior to old-age pension eligibility) and those who retired via the standard pathway. METHODS: The study sample comprised 7210 participants from the Norwegian Trøndelag Health Study (HUNT4 70+, 2017-2019) who had worked for at least one year in 1967-2019, worked until age 55+, and retired before HUNT4...
July 2023: International Journal of Geriatric Psychiatry
#24
JOURNAL ARTICLE
Andrea Horta-Barba, Saul Martinez-Horta, Jesús Pérez-Pérez, Arnau Puig-Davi, Natascia de Lucia, Giuseppe de Michele, Elena Salvatore, Stefanie Kehrer, Josef Priller, Simone Migliore, Ferdinando Squitieri, Anna Castaldo, Caterina Mariotti, Veronica Mañanes, Jose Luis Lopez-Sendon, Noelia Rodriguez, Asunción Martinez-Descals, Filipa Júlio, Cristina Januário, Marianna Delussi, Marina de Tommaso, Sandra Noguera, Jesús Ruiz-Idiago, Emilia J Sitek, Renata Wallner, Angela Nuzzi, Javier Pagonabarraga, Jaime Kulisevsky
BACKGROUND: Progressive cognitive decline is an inevitable feature of Huntington's disease (HD) but specific criteria and instruments are still insufficiently developed to reliably classify patients into categories of cognitive severity and to monitor the progression of cognitive impairment. METHODS: We collected data from a cohort of 180 positive gene-carriers: 33 with premanifest HD and 147 with manifest HD. Using a specifically developed gold-standard for cognitive status we classified participants into those with normal cognition, those with mild cognitive impairment, and those with dementia...
November 2023: Journal of Neurology
#25
EDITORIAL
Maria Basta, Eleni Skourti
Since the COVID-19 pandemic outburst, numerous studies have reported on the holistic approach of the disease, which has negative consequences on physical and mental health as well as short- and long-term effects on cognition, independently of age. The context of the pandemic brought significant demands on public health systems, leading to restrictive measures against coronavirus expansion (quarantines, physical distancing policies, etc.). Such measures are reported to increase perceived loneliness and helplessness and may exacerbate feelings of emotional distress...
July 14, 2023: Psychiatrikē, Psychiatriki
#26
JOURNAL ARTICLE
Mohammad Al Olaimat, Jared Martinez, Fahad Saeed, Serdar Bozdag
MOTIVATION: Alzheimer's disease (AD) is a neurodegenerative disease that affects millions of people worldwide. Mild cognitive impairment (MCI) is an intermediary stage between cognitively normal state and AD. Not all people who have MCI convert to AD. The diagnosis of AD is made after significant symptoms of dementia such as short-term memory loss are already present. Since AD is currently an irreversible disease, diagnosis at the onset of the disease brings a huge burden on patients, their caregivers, and the healthcare sector...
June 30, 2023: Bioinformatics
#27
JOURNAL ARTICLE
Patricia Diaz-Galvan, Giulia Lorenzon, Rosaleena Mohanty, Gustav Mårtensson, Enrica Cavedo, Simone Lista, Andrea Vergallo, Kejal Kantarci, Harald Hampel, Bruno Dubois, Michel J Grothe, Daniel Ferreira, Eric Westman
BACKGROUND: Donepezil is an approved therapy for the treatment of Alzheimer's disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants. We investigated whether response to donepezil differs in mild cognitive impaired (MCI) individuals demonstrating different magnetic resonance imaging (MRI) subtypes. METHODS: From the Hippocampus Study double-blind, randomized clinical trial, we included 173 MCI individuals (donepezil = 83; placebo = 90) with structural MRI data, at baseline and at clinical follow-up assessments (6-12-month)...
June 23, 2023: Alzheimer's Research & Therapy
#28
JOURNAL ARTICLE
Kevin Duff, Ava Dixon, Lindsay Embree
Practice effects have become a potentially important variable regarding the diagnosis, prognosis, and treatment recommendations in mild cognitive impairment (MCI) and Alzheimer's disease (AD). However, the understanding of these short-term changes in test scores remains unclear. The current observational study sought to examine variables that influence the magnitude of short-term practice effects in MCI and AD, including demographic information, cognitive performance, daily functioning, and medical comorbidities...
June 15, 2023: Archives of Clinical Neuropsychology: the Official Journal of the National Academy of Neuropsychologists
#29
JOURNAL ARTICLE
Khantamat Thammachat, Sawit Na Songkhla, Daruj Aniwattanapong, Duangporn Suriyaamarit
BACKGROUND: Evaluating quiet stance under various conditions using nonlinear analysis may be an effective method of measuring postural control in older adults with mild cognitive impairment (MCI). However, no studies have examined the reliability of using sample entropy (SampEn) in older adults with MCI. RESEARCH QUESTION: What are the within- and between-session reliability and minimal detectable change (MDC) of a nonlinear analysis measure of postural control during quiet stance in older adults with MCI? METHODS: Fourteen older adults with MCI performed static standing under four conditions, and the center of pressure signal was calculated and applied to SampEn nonlinear analysis...
June 7, 2023: Gait & Posture
#30
JOURNAL ARTICLE
Jose Bernal, Stefanie Schreiber, Inga Menze, Anna Ostendorf, Malte Pfister, Jonas Geisendörfer, Aditya Nemali, Anne Maass, Renat Yakupov, Oliver Peters, Lukas Preis, Luisa Schneider, Ana Lucia Herrera, Josef Priller, Eike Jakob Spruth, Slawek Altenstein, Anja Schneider, Klaus Fliessbach, Jens Wiltfang, Björn H Schott, Ayda Rostamzadeh, Wenzel Glanz, Katharina Buerger, Daniel Janowitz, Michael Ewers, Robert Perneczky, Boris-Stephan Rauchmann, Stefan Teipel, Ingo Kilimann, Christoph Laske, Matthias H Munk, Annika Spottke, Nina Roy, Laura Dobisch, Peter Dechent, Klaus Scheffler, Stefan Hetzer, Steffen Wolfsgruber, Luca Kleineidam, Matthias Schmid, Moritz Berger, Frank Jessen, Miranka Wirth, Emrah Düzel, Gabriel Ziegler
BACKGROUND: White matter hyperintensities (WMH) in subjects across the Alzheimer's disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology-not just arterial hypertension-impacts WMH, which in turn adversely influences cognition. Here we seek to determine the effect of both hypertension and Aβ positivity on WMH, and their impact on cognition. METHODS: We analysed data from subjects with a low vascular profile and normal cognition (NC), subjective cognitive decline (SCD), and amnestic mild cognitive impairment (MCI) enrolled in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and Dementia Study (n = 375, median age 70...
May 24, 2023: Alzheimer's Research & Therapy
#31
JOURNAL ARTICLE
Yan Wang, Ying Li, Yan Li, Tingting Li, Qi Wang, Qigeng Wang, Shuman Cao, Fangyu Li, Jianping Jia
BACKGROUND: Blood tests would be much easier to implement in the clinical diagnosis of Alzheimer's disease (AD) as minimally invasive measurements. Multiple inspection technologies promoted AD-associated blood biomarkers' exploration. However, there was a lack of further screening and validation for these explored blood-based biomarkers. We selected four potential biomarkers to explore their plasma levels in AD and amnestic mild cognitive impairment (aMCI) and developed a composite panel for AD and aMCI screening...
May 16, 2023: Biomarker Research
#32
JOURNAL ARTICLE
Hanan Ehtewish, Areej Mesleh, Georgios Ponirakis, Alberto De la Fuente, Aijaz Parray, Ilham Bensmail, Houari Abdesselem, Marwan Ramadan, Shafi Khan, Mani Chandran, Raheem Ayadathil, Ahmed Elsotouhy, Ahmed Own, Hanadi Al Hamad, Essam M Abdelalim, Julie Decock, Nehad M Alajez, Omar Albagha, Paul J Thornalley, Abdelilah Arredouani, Rayaz A Malik, Omar M A El-Agnaf
Dementia is a progressive and debilitating neurological disease that affects millions of people worldwide. Identifying the minimally invasive biomarkers associated with dementia that could provide insights into the disease pathogenesis, improve early diagnosis, and facilitate the development of effective treatments is pressing. Proteomic studies have emerged as a promising approach for identifying the protein biomarkers associated with dementia. This pilot study aimed to investigate the plasma proteome profile and identify a panel of various protein biomarkers for dementia...
May 1, 2023: International Journal of Molecular Sciences
#33
JOURNAL ARTICLE
Daniele Altomare, Frederik Barkhof, Camilla Caprioglio, Lyduine E Collij, Philip Scheltens, Isadora Lopes Alves, Femke Bouwman, Johannes Berkhof, Ingrid S van Maurik, Valentina Garibotto, Christian Moro, Julien Delrieu, Pierre Payoux, Laure Saint-Aubert, Anne Hitzel, José Luis Molinuevo, Oriol Grau-Rivera, Juan Domingo Gispert, Alexander Drzezga, Frank Jessen, Philip Zeyen, Agneta Nordberg, Irina Savitcheva, Vesna Jelic, Zuzana Walker, Paul Edison, Jean-François Demonet, Rossella Gismondi, Gill Farrar, Andrew W Stephens, Giovanni B Frisoni
IMPORTANCE: Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect. OBJECTIVE: To assess the clinical effect of amyloid PET in memory clinic patients. DESIGN, SETTING, AND PARTICIPANTS: The AMYPAD-DPMS is a prospective randomized clinical trial in 8 European memory clinics...
May 8, 2023: JAMA Neurology
#34
JOURNAL ARTICLE
Jennifer Avery, David Thomas, Olha Myshakivska
OBJECTIVES: Understanding the negative consequences of Mild Cognitive Impairment (MCI) in Ukraine among a population who have collectively experienced difficult life events, provided the impetus for the current study which analyzed whether the perception of psychological distress differed among older adults with two types of MCI (amnestic MCI [aMCI] & nonamnestic MCI [naMCI]) compared to their cognitively intact peers. METHOD: A sample of 132 older adults were selected from an outpatient regional hospital in Lviv, Ukraine and assigned into either an MCI or non-MCI control group...
April 26, 2023: BMC Geriatrics
#35
JOURNAL ARTICLE
Marta M Dolcet-Negre, Laura Imaz Aguayo, Reyes García de Eulate, Gloria Martí-Andrés, Marta Fernández Matarrubia, Pablo Domínguez, Mará A Fernández Seara, Mario Riverol
BACKGROUND: Subjective cognitive decline (SCD) may represent a preclinical stage of Alzheimer's disease (AD). Predicting progression of SCD patients is of great importance in AD-related research but remains a challenge. OBJECTIVE: To develop and implement an ensemble machine learning (ML) algorithm to identify SCD subjects at risk of conversion to mild cognitive impairment (MCI) or AD. METHODS: Ninety-nine SCD patients were included. Thirty-two progressed to MCI/AD, while 67 remained stable...
March 13, 2023: Journal of Alzheimer's Disease: JAD
#36
JOURNAL ARTICLE
Stephen M Rao, Rachel Galioto, Megan Sokolowski, Madelyn Pierce, Lisa Penn, Anna Sturtevant, Blazenka Skugor, Brent Anstead, James B Leverenz, David Schindler, David Blum, Jay L Alberts, Lori Posk
BACKGROUND: The self-administered iPad-based Cleveland Clinic Cognitive Battery (C3B) was designed specifically for the efficient screening of cognitive functioning of older adults in a primary care setting. OBJECTIVE: 1) Generate regression-based norms from healthy participants to enable demographic corrections to facilitate clinical interpretation; 2) estimate test-retest reliability and practice effects; 3) examine ability to discriminate mild cognitive impairment (MCI) from healthy aging; 4) d etermine validity of screening in a distracting clinical environment; and 5) determine completion rates and patient satisfaction in a primary care setting...
February 20, 2023: Journal of Alzheimer's Disease: JAD
#37
Mohammad Al Olaimat, Jared Martinez, Fahad Saeed, Serdar Bozdag
Alzheimer's disease (AD) is a neurodegenerative disease that affects millions of people worldwide. Mild cognitive impairment (MCI) is an intermediary stage between cognitively normal (CN) state and AD. Not all people who have MCI convert to AD. The diagnosis of AD is made after significant symptoms of dementia such as short-term memory loss are already present. Since AD is currently an irreversible disease, diagnosis at the onset of disease brings a huge burden on patients, their caregivers, and the healthcare sector...
January 31, 2023: bioRxiv
#38
JOURNAL ARTICLE
Michael H Rosenbloom, Terry Barclay
Prodromal Alzheimer's disease (AD) is a neurodegenerative condition typically progressing to dementia within 3 years. We describe a case of a mild cognitive impairment (MCI) patient with biomarker evidence for amyloidosis, tau, and neurodegeneration who had minimal changes in clinical phenotype during an 11-year period. AD biomarkers were obtained with cerebrospinal fluid analysis and amyloid PET imaging, both of which supported a biological diagnosis of AD. However, the patient's neuropsychological profile remained stable over 11 years except for mild memory-retrieval changes...
2023: JAD Reports
#39
JOURNAL ARTICLE
Davangere P Devanand, Arjun V Masurkar, Thomas Wisniewski
INTRODUCTION: Mild to moderate exercise may decrease Alzheimer's disease (AD) risk, but the effects of vigorous, regular physical exercise remain unclear. METHODS: Two patients with initial diagnoses of amnestic mild cognitive impairment (MCI) demonstrated positive AD biomarkers throughout 16 and 8 years of follow-up, with final diagnoses of mild AD and amnestic MCI, respectively. RESULTS: Patient 1 was diagnosed with amnestic MCI at age 64...
February 1, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#40
JOURNAL ARTICLE
Suhail Ahmad Dar, Nasheed Imtiaz
AIM: Particle swarm optimization (PSO) is an algorithm that involves the optimization of Non-linear and Multidimensional problems to reach the best solutions with minimal parameterization. This metaheuristic model has frequently been used in the Pathological domain. This optimization model has been used in diverse forms while predicting Alzheimer's disease. It is a robust algorithm that works on linear and multi-modal data while predicting Alzheimer's disease. PSO techniques have been in action for quite some time for detecting various diseases and this paper systematically reviews the papers on various kinds of PSO techniques...
January 31, 2023: Applied Neuropsychology. Adult
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
